DCPH vs. AGIO, FPRX, SNDX, XNCR, ALXO, ROIV, ELAN, INSM, ASND, and LEGN
Should you be buying Deciphera Pharmaceuticals stock or one of its competitors? The main competitors of Deciphera Pharmaceuticals include Agios Pharmaceuticals (AGIO), Five Prime Therapeutics (FPRX), Syndax Pharmaceuticals (SNDX), Xencor (XNCR), ALX Oncology (ALXO), Roivant Sciences (ROIV), Elanco Animal Health (ELAN), Insmed (INSM), Ascendis Pharma A/S (ASND), and Legend Biotech (LEGN). These companies are all part of the "medical" sector.
Agios Pharmaceuticals (NASDAQ:AGIO) and Deciphera Pharmaceuticals (NASDAQ:DCPH) are both mid-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, community ranking, media sentiment, dividends and profitability.
Deciphera Pharmaceuticals has a net margin of -108.86% compared to Deciphera Pharmaceuticals' net margin of -1,199.26%. Deciphera Pharmaceuticals' return on equity of -41.41% beat Agios Pharmaceuticals' return on equity.
71.0% of Deciphera Pharmaceuticals shares are owned by institutional investors. 4.9% of Agios Pharmaceuticals shares are owned by company insiders. Comparatively, 4.7% of Deciphera Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Agios Pharmaceuticals has a beta of 0.77, indicating that its stock price is 23% less volatile than the S&P 500. Comparatively, Deciphera Pharmaceuticals has a beta of 0.19, indicating that its stock price is 81% less volatile than the S&P 500.
Agios Pharmaceuticals received 158 more outperform votes than Deciphera Pharmaceuticals when rated by MarketBeat users. Likewise, 67.51% of users gave Agios Pharmaceuticals an outperform vote while only 64.91% of users gave Deciphera Pharmaceuticals an outperform vote.
Agios Pharmaceuticals presently has a consensus price target of $35.00, indicating a potential downside of 15.85%. Deciphera Pharmaceuticals has a consensus price target of $24.17, indicating a potential downside of 5.40%. Given Agios Pharmaceuticals' higher probable upside, analysts clearly believe Deciphera Pharmaceuticals is more favorable than Agios Pharmaceuticals.
Deciphera Pharmaceuticals has higher revenue and earnings than Agios Pharmaceuticals. Deciphera Pharmaceuticals is trading at a lower price-to-earnings ratio than Agios Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, Agios Pharmaceuticals had 21 more articles in the media than Deciphera Pharmaceuticals. MarketBeat recorded 27 mentions for Agios Pharmaceuticals and 6 mentions for Deciphera Pharmaceuticals. Agios Pharmaceuticals' average media sentiment score of 1.09 beat Deciphera Pharmaceuticals' score of 0.27 indicating that Deciphera Pharmaceuticals is being referred to more favorably in the news media.
Summary
Agios Pharmaceuticals beats Deciphera Pharmaceuticals on 10 of the 18 factors compared between the two stocks.
Get Deciphera Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for DCPH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DCPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Deciphera Pharmaceuticals Competitors List
Related Companies and Tools
